OMER — Omeros Corporation

Omeros Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Income: $56.1 million, or $0.78 per share, influenced by a $73.1 million noncash mark-to-market gain related to 2029 convertible notes.
• Adjusted Net Loss: Excluding the noncash item, the adjusted net loss was $17.1 million, or $0.24 per share.
• Revenue: Gross revenues from YARTEMLEA were $11.1 million, with net revenues of $9.9 million after an 11% gross-to-net adjustment.
• Cash Position: Ended the quarter with $135.3 million in cash and investments, following the retirement of remaining 2026 convertible notes.
• Share Repurchase: Approximately 360,000 shares repurchased at an average price of $11.70 per share, totaling $4.2 million.

2. Strategic Updates and Business Highlights

• YARTEMLEA Launch: Successfully launched in January 2026, becoming the first approved treatment for TA-TMA. Initial demand is strong, with 30 unique accounts ordering the product by March 31.
• Partnership with Novo Nordisk: Closed a transaction providing $240 million upfront, with potential for $100 million in milestone payments, supporting YARTEMLEA's launch.
• Regulatory Developments: CMS assigned a permanent J-code for YARTEMLEA, effective July 1, to simplify billing and reimbursement. NTAP approval is anticipated in August, effective October 1.
• Pipeline Expansion: Ongoing development of additional MASP-2 inhibitors and other programs, including OMS527 for cocaine use disorder and OncotoX-AML for acute myeloid leukemia.

3. Forward Guidance and Outlook

• Operating Expenses: Expected to increase slightly in Q2 2026, particularly in sales and marketing as the company builds its commercial infrastructure.
• Revenue Guidance: No specific revenue guidance provided for YARTEMLEA due to the early stage of the launch and ongoing market access developments.
• Interest Expense: Anticipated to be approximately $7.1 million in Q2, reflecting reduced debt levels.

4. Bad News, Challenges, or Points of Concern

• Volatility in Financial Metrics: The noncash mark-to-market adjustments on convertible notes can introduce significant volatility in reported results, complicating the assessment of operational performance.
• Competition: Concerns regarding AstraZeneca's Ultomiris Phase III study in TMA, which has changed its endpoints and may impact the competitive landscape.
• Market Adoption: While early adoption is promising, ongoing efforts are needed to ensure broader acceptance and utilization of YARTEMLEA among healthcare providers.

5. Notable Q&A Insights

• YARTEMLEA Demand: The distribution process is efficient, with deliveries occurring within 24 hours. Initial feedback from clinicians is positive, with a notable adoption rate among pediatric patients.
• Inventory Management: Distributors maintain a small inventory due to the quick delivery system. The number of patients on YARTEMLEA is not disclosed, but it is expected to be larger than the number of accounts ordering the drug.
• P&T Committee Approvals: The company is seeing faster-than-expected approvals, with a majority anticipated in the coming months, which should enhance access to YARTEMLEA.
• Impact of J-code and NTAP: Both are expected to streamline reimbursement processes and potentially drive higher utilization of YARTEMLEA once implemented.

Overall, Omeros Corporation is positioned for growth with the successful launch of YARTEMLEA and a strong financial foundation, although it faces challenges related to market adoption and competitive pressures.